Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 05/27 10:16:50 am
79.55 CHF   +0.25%
05/26 Anacor received rival bid before Pfizer deal - filing
05/26 NOVARTIS : Creating the sights and sounds
05/25 NOVARTIS : highlights its strong foundation for long-term, sustainab..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Anacor received rival bid before Pfizer deal - filing

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/26/2016 | 11:29pm CEST
The Pfizer logo is seen at their world headquarters in New York

Anacor Pharmaceuticals Inc (>> Anacor Pharmaceuticals Inc) had received an offer from a third party before it agreed to be bought by Pfizer Inc (>> Pfizer Inc.) in a $5.2 billion (£4 billion) deal last week, regulatory filings showed.

Anacor Pharmaceuticals Inc (>> Anacor Pharmaceuticals Inc) had received an offer from a third party before it agreed to be bought by Pfizer Inc (>> Pfizer Inc.) in a $5.2 billion (£4 billion) deal last week, regulatory filings showed.

Pfizer agreed to buy Anacor on May 16 to add an eczema gel to its portfolio, a month after the U.S. drug major scrapped plans to acquire Allergan Plc (>> Allergan, Inc.).

At the time, some analysts said they had expected Anacor to be acquired by Allergan, which has a stronger presence in the dermatology market, or by Novartis AG's (>> Novartis AG) Sandoz unit, which sells Anacor's toenail fungus drug in the United States.

Anacor said in a regulatory filing on Thursday that Pfizer originally offered $95 per share on May 6 but its financial adviser, Citi, recommended the company improve the bid, given Anacor had received another offer. (http://1.usa.gov/1XVlbSw)

On May 13, Pfizer communicated to Citi its "best and final" offer of $99.25 per share, while the other bidder said it was ready to offer $90 per share, and an additional $500 million if crisaborole generated net sales of more than $1 billion in the first eight quarters post launch.

Anacor's crisaborole is currently being reviewed by the U.S. Food and Drug Administration.

Some analysts have also said the relatively low termination fee of about $181 million could persuade Anacor to accept a superior proposal.

Anacor's shares ended the day up about 1 percent at $100.07 on Thursday. They had closed above Pfizer's offer price for eight of the nine days since May 16.

(Reporting by Natalie Grover in Bengaluru; Editing by Maju Samuel and Sriraj Kalluvila)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on NOVARTIS AG
05/26 Anacor received rival bid before Pfizer deal - filing
05/26 CATALENT : Strengthens Leadership Position in Asia-Pacific with Key Appointments..
05/26 NOVARTIS : Creating the sights and sounds
05/25 NOVARTIS : highlights its strong foundation for long-term, sustainable growth at..
05/25 NOVARTIS : highlights its strong foundation for long-term, sustainable growth at..
05/24 NOVARTIS : Sandoz' biosimilar rituximab regulatory submission accepted by Europe..
05/23DJSAMSUNG ELECTRONICS : Targets U.S. Drug Market With Remicade Knockoff
05/23 NOVARTIS' : Entresto given strong Class I recommendation in both US and EU heart..
05/22 NOVARTIS : New cancer drug on NHS
05/21 NOVARTIS' : Entresto® given strong Class I recommendation in both US and EU hear..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials